

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
02190	ZYLOXTB-B	2021/06/25	2021/07/02	2021/07/05

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2021/06/22-2021/06/25
Closing Time for Margin Application	2021/06/24 2:00pm
Subscription Fee	HKD 100
Days For Margin Financing	6 days
Indicative Interest Rate	1.98% (0.25% deductible [^]) [^] Eligible new and existing customers who use the electronic direct debit authorization (eDDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)

Share Offer Highlights

Total Number of Offer Shares:	60,000,000 H Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	6,000,000 H Shares (subject to reallocation)
- Number of Placing Shares:	54,000,000 H Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 39.80-42.70 per Share
2020 Historical P/E ratio:	-
Sponsor:	Morgan Stanley, CITIC Securities

Company Overview

The Company is a leading player in the neuro- and peripheral-vascular interventional medical device market in China in terms of its comprehensive product portfolio. Its current therapeutic areas include acute ischemic stroke (AIS), intracranial aneurysm, carotid artery stenosis, peripheral arterial and venous diseases, and dialysis related diseases. It provides solutions to patients and physician with the most comprehensive product portfolio covering neuro- and peripheral-vascular interventional medical devices among domestic neuro- and peripheral-vascular medical device companies in China according to Frost & Sullivan. Its current neurovascular product portfolio covers a full suite of products in five major categories, namely ischemic, hemorrhagic, stenosis, carotid artery, vascular access device, and according to Frost & Sullivan, it is the only domestic company in China that has developed a neurovascular product portfolio covering all these five major categories. With 22 approved products and product candidates, it has the most comprehensive peripheral-vascular interventional product portfolio among domestic players in China covering a full spectrum of arterial and venous products including stents, balloons, catheters and filters, according to Frost & Sullivan.

For the year ended December 31, 2019 and 2020, the Company's net losses were RMB 66.65 mn, and RMB 100.47 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463



Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan

(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.